2. Search Result
Search Result
Results for "

BXPC-3

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Fluorescent Dye

3

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N1410
    Triacetylresveratrol

    		STAT NF-κB Cancer
    Triacetylresveratrol, an acetylated analog of Resveratrol. Triacetylresveratrol decreases the phosphorylation of STAT3 and NF-κB in a dose- and time- dependent manner in PANC-1 and BxPC-3 cells. Anticancer effects .
    Triacetylresveratrol
  • HY-156328
    NSC 48160

    		Apoptosis Cancer
    NSC 48160 inhibits the growth of the pancreatic cancer cells with IC50s of 84.3 μM for CPFAC-1 and 94.5 μM for BxPC-3. NSC 48160 also induces pancreatic cancer cell apoptosis. NSC 48160 can improve metabolic syndromes, such as NASH, obesity and lipid metabolism disorders .
    NSC 48160
  • HY-18597
    LB-100
    5+ Cited Publications

    		 Phosphatase Cancer
    LB-100 is a protein phosphatase 2A (PP2A) inhibitor, with IC50 of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells [3].
    LB-100
  • HY-160496
    STAT3-IN-25

    		STAT Cancer
    STAT3-IN-25 (compound 2p) is a potent STAT3 inhibitor with a p-trifluoroethoxy benzyl substituent. STAT3-IN-25 shows STAT3 luciferase inhibition activity using HEK293T cells with an IC50 of 22.3 nM and ATP production inhibition activity using BxPC-3 cells with an IC50 of 32.5 nM. STAT3-IN-25 shows potent antiproliferation activities on BxPC-3 and Capan-2 cells. STAT3-IN-25 has the potential for pancreatic cancer research .
    STAT3-IN-25
  • HY-172150
    XH02

    		Biochemical Assay Reagents Cancer
    XH02 is a compound based on L6 modification. XH02 ( 177Lu labeled) displays exceptional tumor growth inhibition in BxPC-3 tumors .
    XH02
  • HY-161614
    Tubulin inhibitor 44

    		Microtubule/Tubulin Cancer
    Tubulin inhibitor 44 (Compound 26r) is an inhibitor for tubullin. Tubulin inhibitor 44 exhibits cytotoxicity in cancer cells NCI-H460, BxPC-3 and HT-29, with IC50s of 0.96, 0.66 and 0.61 nM, respectively .
    Tubulin inhibitor 44
  • HY-173074
    Microtubulin-IN-1

    		Microtubule/Tubulin MDM-2/p53 Apoptosis Cancer
    Microtubulin-IN-1 (Compound 8g) is the inhibitor for microtubulin that targets colchicine-binding site, disrupts the microtubulin integrity, and induces the upregulation of p53. Microtubulin-IN-1 exhibits antiproliferative activity in a variety of cancer cell lines (IC50 for NCI-H460, BxPC-3 and HT-29 is 2.4, 1.6 and 2.07 nM, respectively), arrests the cell cycle at G2/M phase, and induces apoptosis in NCI-H460 .
    Microtubulin-IN-1
  • HY-147725
    Microtubule inhibitor 4

    		Microtubule/Tubulin Cancer
    Microtubule inhibitor 4 (compound 2) is a potent microtubule inhibitor. Microtubule inhibitor 4 shows cytotoxicity with IC50s of 4.0, 3.2, 2.1 nM for NCI-H460, BxPC-3, HT-29 cells, respectively. Microtubule inhibitor 4 shows the inhibition of tubulin polymerization .
    Microtubule inhibitor 4
  • HY-147727
    Microtubule inhibitor 6

    		Microtubule/Tubulin Cancer
    Microtubule inhibitor 6 (compound 17o) is a potent microtubule inhibitor. Microtubule inhibitor 6 shows cytotoxicity with IC50s of 14.0, 6.6, 7.0 nM for NCI-H460, BxPC-3, HT-29 cells, respectively. Microtubule inhibitor 6 efficiently inhibits microtubule polymerization .
    Microtubule inhibitor 6
  • HY-163715
    Antitumor agent-165

    		FAK Cancer
    Antitumor agent-165 (Compound 10l) is a potent focal adhesion kinase (FAK) inhibitor. Antitumor agent-165 exhibits effective antiproliferative activity against CAPAN-1, PANC-1, PATU-T, SUIT-2, BxPC-3, PDAC-3 and PANC-1 GR with IC50s in the range of 1.04-3.44 μM .
    Antitumor agent-165
  • HY-169369
    TRAP-1

    XJZ-06-462

    		 MDM-2/p53 Autophagy Apoptosis Cancer
    TRAP-1 (XJZ-06-462) is ap53 transcriptional activator that effectively activates mutant p53 and triggers the transcription of p53 target genes. TRAP-1 rapidly upregulates p21 and other p53 target genes in pancreatic cell lines with p53Y220C. TRAP-1 inhibits cell proliferation, with IC50 values of 3.94 and 0.531 μM in BxPC-3 and A549 cells, respectively. TRAP-1 regulates autophagy in lung cancer cells and offers protective effects against oxidative stress and cell apoptosis [3].
    TRAP-1
  • HY-144311
    OXPHOS-IN-1

    		Oxidative Phosphorylation Mitochondrial Metabolism Cancer
    OXPHOS-IN-1 (compound 2) is a oxidative phosphorylation (OXPHOS) inhibitor. OXPHOS-IN-1 inhibits the cells growth of MIA PaCa-2 and BxPC-3 cells with IC50s of 2.34 μM and 13.82 μM, respectively .
    OXPHOS-IN-1
  • HY-402237
    Nampt-IN-15

    		NAMPT Cancer
    Nampt-IN-15 (Example 3) is an Nampt inhibitor. Nampt-IN-15 shows cytotoxicity against BxPC-3, HepG2, L540cy and MOLM-13, with IC50s of 38.5 nM, 8 nM, 8.5 nM, 7 nM respectively .
    Nampt-IN-15
  • HY-158726
    Complex 3

    		Fluorescent Dye Cancer
    Complex 3 is a fluorescent dithiocarbazate-copper complex with anticancer activity, which localizes to mitochondria. Complex 3 displays excitation/emission maxima of 455-495/535 nm, respectively. Complex 3 inhibits the growth of BxPC-3, AsPC-1, PANC-1, and WI38 pancreatic cancer cells with IC50 values of 0.74, 0.41, 0.62, and 2.06 µM, respectively. Complex 3 induces lipid peroxidation and mitochondrial rupture and shrinkage in AsPC-1 cells. Complex 3 also induces mitochondrial apoptosis and cytokine-cytokine receptor interaction dysfunction in AsPC-1 cells. Complex 3 reduces tumor volume and intratumor apoptosis in an AsPC-1 mouse xenograft model .
    Complex 3
  • HY-152204
    Cathepsin L/S-IN-1

    		Cathepsin Cancer
    Cathepsin L/S-IN-1 is a dual inhibitor of Cathepsin L and Cathepsin S with IC50s of 4.10 μM and 1.79 μM, respectively. Cathepsin L/S-IN-1 shows a significant antimetastatic and invasive effects on pancreatic cancer BxPC-3 and PANC-1 cells .
    Cathepsin L/S-IN-1
  • HY-120561
    PC-046

    		Trk Receptor IRAK Pim Apoptosis Cancer
    PC-046 is a multi-target inhibitor for tyrosine receptor kinase B (TrkB), IRAK-4 and Pim-1, with IC50 of 13.4 μM, 15.4 μM and 19.1 μM, respectively. PC-046 exhibits cytotoxicity against pancreatic cancer cell BxPC3 with IC50 of 7.5-130 nM. PC-046 induces apoptosis and arrests cell cycle at G2/M phase in BxPC3. PC-046 exhibits antitumor efficacy and exhibits good pharmacokinetic characteristics in mice .
    PC-046
  • HY-170776
    AXL/Angiokinase-IN-1

    		PDGFR VEGFR FGFR Apoptosis Cancer
    AXL/Angiokinase-IN-1 (compound 11b) is an AXL/triple angiokinase inhibitor, IC50=3.75 nM (AXL expression). AXL/Angiokinase-IN-1 inhibits epithelial-mesenchymal transition (EMT) in Bxpc-3, blocking lung cancer cell metastasis. AXL/Angiokinase-IN-1 also inhibits vascular and fibroblast functions, promoting apoptosis (apoptosis) in cancer cells and fibroblasts. AXL/Angiokinase-IN-1 features low toxicity and good metabolic stability .
    AXL/Angiokinase-IN-1
  • HY-161353
    c-Met-IN-23

    		P-glycoprotein c-Met/HGFR Cancer
    c-Met-IN-23 (Compound 12g) is a c-Met inhibitor (IC50 = 0.052 μM for c-Met). c-Met-IN-23 also inhibits MDR1 and MRP1/2 pumps in the cancerous HepG2 and BxPC3 cells. c-Met-IN-23 is an anticancer agent .
    c-Met-IN-23
  • HY-164445
    STAT3-IN-32

    		STAT Cancer
    STAT3-IN-32 (compound 2p) is an orally active, potent STAT3 dual phosphorylation inhibitor with an indole-containing tetra-aromatic heterocycle scaffold. STAT3-IN-32 exhibits STAT3 luciferase inhibition activity using HEK293T cells with an IC50 of 5.3 nM and ATP production inhibition activity using BxPC-3 cells with an IC50 of 4.2 nM. STAT3-IN-32 significantly blocks p-Tyr705 and p-Ser727 and causes the abrogation of the corresponding nuclear transcription and mitochondrial oxidative phosphorylation functions of STAT3 by targeting the STAT3 SH2 domain (KD=21.3 nM). STAT3-IN-32 exhibits significant suppressive effects in a pancreatic cancer xenograft model .
    STAT3-IN-32
  • HY-123597
    NSC 109555

    DDUG; NCI C04808

    		 Autophagy Checkpoint Kinase (Chk) Cancer
    NSC 109555 is an ATP-competitive inhibitor of checkpoint kinase 2 (Chk2; IC50=200 nM in a cell-free kinase assay). It is selective for Chk2 over Chk1 and 16 kinases in a panel but does inhibit Brk, c-Met, IGFR, and LCK with IC50 values of 210, 6,000, 7,400, and 7,100 nM, respectively. NSC 109555 inhibits Chk2 autophosphorylation and phosphorylation of the Chk2 substrate histone H1 in vitro (IC50=240 nM). It inhibits the growth of, and induces autophagy in, L1210 leukemia cells in vitro.2 NSC 109555 (1,250 nM) potentiates gemcitabine-induced cytotoxicity in MIA PaCa-2, CFPAC-1, PANC-1, and BxPC-3 pancreatic cancer cells, as well as reduces gemcitabine-induced increases in Chk2 phosphorylation and enhances gemcitabine-induced production of reactive oxygen species (ROS) in MIA PaCa-2 cells.
    NSC 109555
  • HY-139090
    3-Oxobetulin acetate

    28-O-Acetyl-3-Oxobetulin; 3-oxo-28-O-Acetylbetulin

    		 Bacterial HIV Drug Derivative Cancer
    3-Oxobetulin acetate (28-O-Acetyl-3-Oxobetulin; 3-oxo-28-O-Acetylbetulin) is a derivative of betulin (HY-N0083), a cholesterol biosynthesis inhibitor. 3-Oxobetulin acetate inhibits the growth of P388 murine lymphocytic leukemia cells (EC50=0.12 μg/mL) and human MCF-7 breast cancer, SF-268 CNS cancer, H460 lung cancer, and KM20L2 colon cancer cells (GI50s=8, 10.6, 5.2, and 12.7 μg/mL), but not BxPC-3 pancreatic cancer cells or DU145 prostate cancer cells (GI50s=>10 μg/mL for both). 3-Oxobetulin acetate inhibits the replication of X4-tropic recombinant HIV (NL4.3-Ren) in MT-2 lymphoblastoid cells (IC50=13.4 μM). 3-Oxobetulin acetate is also effective against Listeria donovani amastigotes.
    3-Oxobetulin acetate
  • HY-131203
    PROTAC BRD4 Degrader-6

    		PROTACs Epigenetic Reader Domain Apoptosis c-Myc Caspase Cancer
    PROTAC BRD4 Degrader-6 (compound 32a) is a potent small-molecule BRD4PROTAC degrader with IC50 value of 2.7 nM for BRD4 BD1. PROTAC BRD4 Degrader-6 potently degrades BRD4 protein and inhibits the expression of c-Myc. PROTAC BRD4 Degrader-6 inhibits the proliferation of pancreatic cancer cell line BxPC3 and induces apoptosis. PROTAC BRD4 Degrader-6 can be used for human pancreatic cancer research (Pink: Mivebresib (HY-100015); Black: linker, Azido-PEG1-CH2CO2H (HY-108369); Blue: Lenalidomide (HY-A0003)) .
    PROTAC BRD4 Degrader-6
  • HY-159606
    MS182

    		MDM-2/p53 Cancer
    MS182 (compound 11) is an acetylation targeting chimera (AceTAC) designed based on p53 Y220C stabilizer and targeting p53 Y220C. MS182 is composed of p53 Y220C and p300/CBP binders, respectively, coupled by a linker. MS182 forms a ternary complex with p300/CBP acetyltransferase and p53 Y220C in a time- and concentration-dependent manner, effectively acetylating lysine at position 382 of p53 Y220C (ACE50: 1.52 μM). MS182 also exhibited considerable bioavailability in mice, with GI50 values of 2.16 μM and 1.83 μM for BxPC3 (p53 Y220C/-) and NUGC (p53 Y220C/+), respectively .
    MS182
  • HY-146695
    S100P-IN-1

    		Others Cancer
    S100P-IN-1 (Compound 4) is a S100P inhibitor with an IC50 of 22.7 nM. S100P-IN-1 shows anti-metastatic effects on pancreatic cancer cells .
    S100P-IN-1
  • HY-168489
    OBI-992 drug-linker

    		Drug-Linker Conjugates for ADC Cancer
    OBI-992 drug-linker is a drug-linker conjugate composed of a TOP I inhibitor Exatecan (HY-13631) and a linker. OBI-992 drug-linker exhibits antitumor property in mouse models and can be used for synthesis of ADC OBI-992 .
    OBI-992 drug-linker
  • HY-163401
    Epoxykynin

    		Epoxide Hydrolase Cancer
    Epoxykynin is a potent epoxide hydrolase (sEH) inhibitor .
    Epoxykynin
  • HY-N0326R
    L-Methionine (Standard)

    		Endogenous Metabolite Keap1-Nrf2 Apoptosis Inflammation/Immunology Cancer
    L-Methionine (Standard) is the analytical standard of L-Methionine. This product is intended for research and analytical applications. L-Methionine is an L-isomer of orally active Methionine, an essential amino acid. Methionine is a strong liver antidote that acts as a liver protector. L-Methionine can inhibit cell proliferation and induce cell apoptosis. L-Methionine has antitumor and antioxidant activity [3].
    L-Methionine (Standard)
  • HY-18641
    Ki16198

    		LPL Receptor Cancer
    Ki16198 is a potent and orally active LPA receptor antagonist, the methyl ester of Ki16425 (HY-13285). Ki16198 inhibits LPA1 and LPA3-induced inositol phosphate production with?Ki?values of 0.34 μM and 0.93 μM, respectively. Ki16198 is effective for pancreatic cancer tumorigenesis and metastasis in vivo .
    Ki16198
  • HY-N0326
    L-Methionine
    5 Publications Verification

    		 Endogenous Metabolite Keap1-Nrf2 Apoptosis Inflammation/Immunology Cancer
    L-Methionine is an L-isomer of orally active Methionine, an essential amino acid. Methionine is a strong liver antidote that acts as a liver protector. L-Methionine can inhibit cell proliferation and induce cell apoptosis. L-Methionine has antitumor and antioxidant activity [3].
    L-Methionine
  • HY-14653
    Amsilarotene

    TAC-101; Am 555S

    		 RAR/RXR Apoptosis Cancer
    Amsilarotene (TAC-101; Am 555S), an orally active synthetic retinoid, has selective affinity for retinoic acid receptor α (RAR-α) binding with Ki of 2.4, 400 nM for RAR-α and RAR-β. Amsilarotene induces the apoptotic of human gastric cancer, hepatocellular carcinoma and ovarian carcinoma cells. Amsilarotene can be used for the research of cancer [3].
    Amsilarotene
  • HY-154313
    Spiclomazine

    Clospirazine

    		 Ras Cancer
    Spiclomazine (Clospirazine) is a potent mutant KRAS(G12C) inhibitor that selectively inhibits mutant KRAS-driven pancreatic cancer. Spiclomazine can eliminate KRas-GTP levels in KRAS-driven pancreatic cancer and effectively inhibit RAS-mediated signaling. Spiclomazine significantly inhibits tumor progression in mouse renal capsule xenotransplantation models .
    Spiclomazine
  • HY-149814
    PDK-IN-1

    		PDHK HSP Cancer
    PDK-IN-1 (compound 7o) is a pyruvate dehydrogenase kinase (PDK) inhibitor. PDK-IN-1 shows IC50 values of 0.03 and 0.1 μM for PDK1 and HSP90, respectively. PDK-IN-1 targets PDH/PDK axis thus reducing efficiently the tumor mass .
    PDK-IN-1
  • HY-148712
    SIRT6 activator 12q

    		Apoptosis Sirtuin Cancer
    SIRT6 activator 12q is potent, selective and orally active SIRT6 activator with IC50 values of 171.20, >200, >200, >200, 0.58 μM for SIRT1, SIRT2, SIRT3, SIRT5, SIRT6, respectively. SIRT6 activator 12q inhibits cell growth and migration. SIRT6 activator 12q induces Apoptosis and cell cycle arrest at G2 phase. SIRT6 activator 12q shows anticancer activity .
    SIRT6 activator 12q
  • HY-149927
    Antitumor agent-91

    		Drug Derivative Cancer
    Antitumor agent-91 is a cyclic phosphate ester derivative with anticancer and anti-proliferative activities. Antitumor agent-91 has potential application in human castration resistant prostate cancer and pancreatic cancer .
    Antitumor agent-91
  • HY-147838
    Nampt-IN-9

    		NAMPT Cancer
    Nampt-IN-9 (Compound 8) is a potent NAMPT inhibitor with anticancer activities. Nampt-IN-9 can be used for pancreatic ductal adenocarcinoma research .
    Nampt-IN-9
  • HY-148012
    SOP1812

    QN-302

    		 G-quadruplex Cancer
    SOP1812 (QN-302) is a naphthalene diimide (ND) derivative with anti-tumor activity. SOP1812 binds to quadruplex arrangements (G4s), and down-regulates several cancer gene pathways. SOP1812 shows great affinity to hTERT G4 and HuTel21 G4 with KD values of 4.9 and 28.4 nM, respectively. SOP1812 can be used for the research of cancer .
    SOP1812
  • HY-14389
    LP-261

    		Microtubule/Tubulin Cancer
    LP-261 is a potent and orally active anti-mitotic agent and shows an inhibition of in vitro tubulin polymerization with an EC50 of 3.2 μM . LP-261 inhibits growth of a human non-small-cell lung tumor (NCI-H522) in vivo and can be used for cancer research .
    LP-261
  • HY-173145
    CD13-IN-1

    		Aminopeptidase Cancer
    CD13-IN-1 (Compound 5f) is a CD13 inhibitor with an IC50 of 1.71 μM. CD13-IN-1 can inhibit the proliferation of multiple tumor cells and has anti-tumor activity .
    CD13-IN-1
  • HY-157762
    GPX4-IN-9

    		Glutathione Peroxidase Ferroptosis Cancer
    GPX4-IN-9 (Compound A16) is a glutathione peroxidase 4 (GPX4) inhibitor that specifically targets GPX4 under both in vitro and in vivo conditions, inducing ferroptosis. GPX4-IN-9 exhibits cytotoxicity against pancreatic cancer cells and can be used in cancer research .
    GPX4-IN-9

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: